OMEROS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.4 USD | +7.94% |
|
+11.84% | +3.98% |
| Apr. 01 | Tranche Update on Omeros Corporation's Equity Buyback Plan announced on April 1, 2024. | CI |
| Apr. 01 | Omeros Corporation announces an Equity Buyback for $50 million worth of its shares. | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 6.5M | Capitalization | 197M |
|---|---|---|---|---|---|
| Net income 2024 * | -138M | Net income 2025 * | -135M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 30.3 x |
| P/E ratio 2024 * |
-1.63
x | P/E ratio 2025 * |
-1.89
x | Employees | 198 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on Omeros Corporation
More recommendations
More press releases
| 1 day | +7.94% | ||
| 1 week | +11.84% | ||
| Current month | +7.94% | ||
| 1 month | +6.58% | ||
| 6 months | +200.88% | ||
| Current year | +3.98% |
1 week
3.07
3.48
1 month
2.974.10
Current year
2.615.14
1 year
0.927.80
3 years
0.9218.86
5 years
0.9225.46
10 years
0.9230.23
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 94-06-15 | |
Michael Jacobsen
DFI | Director of Finance/CFO | 65 | 13-07-31 |
Andreas Grauer
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-10-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 12-09-26 |
Leroy Hood
BRD | Director/Board Member | 85 | 01-02-28 |
Thomas Cable
BRD | Director/Board Member | 84 | 94-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 2 M€ | -.--% | ||
| 0.00% | 34 M€ | +1.32% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-01 | 3.4 | +7.94% | 250,752 |
| 24-04-30 | 3.15 | +0.64% | 172,142 |
| 24-04-29 | 3.13 | -0.63% | 197,439 |
| 24-04-26 | 3.15 | +2.94% | 172,888 |
| 24-04-25 | 3.06 | +0.66% | 265,792 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotes
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Companyâs lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
3.4
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.98% | 183M | |
| -1.17% | 102B | |
| +2.87% | 96.09B | |
| +2.13% | 22.28B | |
| -14.77% | 21.4B | |
| -8.79% | 18.14B | |
| -39.98% | 17.02B | |
| -13.21% | 16.09B | |
| +8.55% | 13.83B | |
| +35.75% | 11.97B |
- Stock Market
- Equities
- OMER Stock
